Modelling the Effect of Breakeven Date in Spring Rotation Planner on Production and Profit of a Pasture-Based Dairy System

The breakeven date is the expected date when pasture supply exceeds cow demand. This date is used to plan the rotation rates, slow during the winter, when pasture growth is low and cows are dry, to a fast rotation in spring, when growth is accelerating and most cows lactating. This date is influenced by regional climate, mainly rainfall and soil temperature, which affects timing and rate of growth acceleration. The objective of this modeling exercise was to explore the effect of the breakeven date on milksolids (MS), grass silage, farm cover and economic farm surplus (EFS) over different climate years for the Canterbury region of New Zealand

Calcium Kinetics During Long-Duration Space Flight

Bone loss represents one of the most significant effects of space flight on the human body. Understanding the mechanisms underlying this loss is critical for maintaining crew health and safety during and after flight. This investigation documents the changes in bone metabolism and calcium kinetics during and after space flight. We previously reported calcium studies on three subjects during and after a 115-d stay on the Russian space station Mir. We report here data on an additional three subjects, whose stays on Mir were approximately 4 (n=l) and 6 (n=2) mos. Previously published data are included for comparison

EOS789, a broad-spectrum inhibitor of phosphate transport, is safe with an indication of efficacy in a phase 1b randomized crossover trial in hemodialysis patients

The treatment of hyperphosphatemia remains challenging in patients receiving hemodialysis. This phase 1b study assessed safety and efficacy of EOS789, a novel pan-inhibitor of phosphate transport (NaPi-2b, PiT-1, PiT-2) on intestinal phosphate absorption in patients receiving intermittent hemodialysis therapy. Two cross-over, randomized order studies of identical design (ten patients each) compared daily EOS789 50 mg to placebo with meals and daily EOS789 100 mg vs EOS789 100 mg plus 1600 mg sevelamer with meals. Patients ate a controlled diet of 900 mg phosphate daily for two weeks and began EOS789 on day four. On day ten, a phosphate absorption testing protocol was performed during the intradialytic period. Intestinal fractional phosphate absorption was determined by kinetic modeling of serum data following oral and intravenous doses of 33Phosphate ( 33P). The results demonstrated no study drug related serious adverse events. Fractional phosphate absorption was 0.53 (95% confidence interval: 0.39,0.67) for placebo vs. 0.49 (0.35,0.63) for 50 mg EOS789; and 0.40 (0.29,0.50) for 100 mg EOS789 vs. 0.36 (0.26,0.47) for 100 mg EOS789 plus 1600 mg sevelamer (all not significantly different). The fractional phosphate absorption trended lower in six patients who completed both studies with EOS789 100 mg compared with placebo. Thus, in this phase 1b study, EOS789 was safe and well tolerated. Importantly, the use of 33P as a sensitive and direct measure of intestinal phosphate absorption allows specific testing of drug efficacy. The effectiveness of EOS789 needs to be evaluated in future phase 2 and phase 3 studies